Acrivon (ACRV) Form 4: CEO RSU Tax Withholding & Share Update

Acrivon Therapeutics, Inc. insiders reported routine tax‑related share transactions.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. insiders reported routine tax‑related share transactions. On 11/14/2025, President and CEO Dr. Peter Blume-Jensen had 59,765 shares of common stock withheld by the company at $2.24 per share to cover mandatory tax withholding upon vesting of restricted stock units, leaving him with 2,066,675 shares held directly. On the same date, 490 shares were similarly withheld at $2.24 per share from holdings reported as indirect, leaving 314,706 shares held indirectly. The filing notes that Dr. Blume-Jensen and co-founder and EVP – Business Operations Dr. Kristina Masson are spouses and each disclaims beneficial ownership of the other’s securities except to the extent of their pecuniary interest.

Insider Trade Summary

Exercise Price or Tax Liability: 60,255 shares

Exercise Price or Tax Liability 2 txns

Insider Blume-Jensen Peter, Masson Kristina

Role President and CEO | EVP - Business Operations

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	59,765	$2.24	$134K
Exercise Price or Tax Liability	Common Stock	490	$2.24	$1K

Holdings After Transaction: Common Stock — 2,066,675 shares (Direct); Common Stock — 314,706 shares (Indirect, See Footnote)

Footnotes (3)

1. F1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
2. F2. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
3. F3. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Acrivon Therapeutics (ACRV) report on this Form 4?

The Form 4 reports that on 11/14/2025, President and CEO Dr. Peter Blume-Jensen had 59,765 common shares and an additional 490 common shares withheld by Acrivon Therapeutics at $2.24 per share to satisfy mandatory tax withholding upon vesting of restricted stock units.

Why were Acrivon Therapeutics (ACRV) shares withheld from the insiders?

According to the explanation, the shares were withheld by the issuer to satisfy mandatory tax withholding requirements that arose upon the vesting of restricted stock units, a common method for covering tax obligations on equity awards.

How many Acrivon Therapeutics (ACRV) shares does the CEO hold after these transactions?

After the reported withholding on 11/14/2025, President and CEO Dr. Peter Blume-Jensen beneficially owns 2,066,675 shares of common stock directly, in addition to indirect holdings described in the filing.

What are the indirect Acrivon Therapeutics (ACRV) holdings reported in this Form 4?

Following the 490-share withholding at $2.24 per share, the Form 4 shows 314,706 common shares held indirectly, with the narrative explaining cross-ownership between Dr. Peter Blume-Jensen and co-founder and EVP – Business Operations Dr. Kristina Masson as spouses.

How are the relationships between Acrivon Therapeutics insiders described in the Form 4?

The filing states that Dr. Peter Blume-Jensen is President, CEO and a director and Dr. Kristina Masson is co-founder and EVP – Business Operations and a director. It notes they are spouses and that each disclaims beneficial ownership of the other’s securities except to the extent of their pecuniary interest.

Does this Acrivon Therapeutics (ACRV) Form 4 indicate an open-market sale by insiders?

No. The transaction code is F, and the explanation clarifies that the shares were withheld by the issuer to satisfy mandatory tax withholding upon restricted stock unit vesting, rather than discretionary open-market sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/18/2025 - 04:28 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		F(1)		59,765	D	$2.24	2,066,675	D(2)
Common Stock	11/14/2025		F(1)		490	D	$2.24	314,706	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

1. Name and Address of Reporting Person^*

Masson Kristina

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP - Business Operations

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

2. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

3. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

	/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen	11/18/2025
	/s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.